PubMed Health⌕ Search

PubMed · 12507174

An automated exposure system for human inhalation study.

Abstract

The authors developed a computer-based exposure system for human inhalation research to study the toxicokinetics of gases. The system uses a set of computer-controlled solenoid valves that regulates inhaled gases and collect exhaled breaths from the subject in accordance with a predetermined time schedule. The volunteer's breathing activity is monitored simultaneously with a real-time instrument, calibrated by both internal and external standards. The common air pollutant, 1,3-butadiene, was used for system validation. The results indicated that the errors were less than 3% relative to reference standards, and the error in the timing of the valve operation was negligible. The average difference between breath-monitoring methods was within 10%. The proposed system is an easy-to-use, reliable device for human studies; more than 130 subjects were tested in a companion study.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yu-Sheng Lin, Thomas J Smith, Peng-Yau Wang. An automated exposure system for human inhalation study.. https://doi.org/10.1080/00039890209602939

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗